Design Therapeutics (DSGN) Free Cash Flow (2020 - 2026)

Design Therapeutics has reported Free Cash Flow for 7 years, with the latest figure at -$15.5 million in Q2 2026.

• Free Cash Flow for Q2 2026 came in at -$15.5 million, down 7.0% year-over-year; the trailing twelve-month figure through Jun 2026 was -$55.1 million (down 8.58% YoY), and the FY2025 annual result was -$54.6 million, down 25.56% from the prior year.
• Free Cash Flow climbed to -$15.5 million in Q2 2026, from -$16.4 million in the prior quarter.
• Over five years, Free Cash Flow peaked at -$9.5 million in Q3 2024 and troughed at -$17.5 million in Q1 2023.
• A 5-year average of -$13.4 million and a median of -$13.4 million in 2023 frame the typical range for Free Cash Flow.
• The widest annual swing landed in 2022, when Free Cash Flow slumped 219.12%; it then jumped 34.67% in 2024.
• A 5-year view of Free Cash Flow shows it stood at -$15.4 million in 2022, then gained by 16.61% to -$12.8 million in 2023, then grew by 23.12% to -$9.9 million in 2024, then declined by 21.7% to -$12.0 million in 2025, then declined by 29.54% to -$15.5 million in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were -$15.5 million in Q2 2026, -$16.4 million in Q1 2026, and -$12.0 million in Q4 2025.